TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.